28.04.2010 10:35:00
|
Phase Forward to Lead Sessions at CDISC Interchange Europe 2010 and Participate in Additional Key Industry Events in April
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will participate in four industry events in April including CDISC Interchange Europe 2010, April 26-30 at the Lancaster London Hotel in London.
At CDISC Interchange Europe, Phase Forward representatives will lead two talks on key industry data standards and drug safety related issues:
Who: |
Alison Sanders, Principal Clinical Design Consultant, Phase Forward | ||||||
What: |
"Building an eCRF CDASH Library – A Case Study” | ||||||
When: |
Wednesday, April 28, 11:00 a.m. – 12:30 p.m. GMT | ||||||
Who: |
Wayne Kubick, Vice President, Phase Forward’s Lincoln Safety Group and member of the CDISC Board of Directors | ||||||
What: |
"The Future of Clinical Data: The Evolving Impact of CDISC and HL7 Standards on Data Management, Submission and Pharmacovigilance” | ||||||
When: |
Thursday, April 29, 4:15 – 5:30 p.m. GMT |
Phase Forward will also exhibit its integrated clinical research suite (ICRS) at the 19th Annual Partnerships in Clinical Trials, April 12-14 in Orlando, Fla.; Bio-IT World Conference & Expo, April 20-22 in Boston, Mass.; and the ACRP Global Conference & Exhibition, April 23-27 in Tampa, Fla.
Members of the media interested in speaking with Phase Forward should contact Maria Sumner at +44 1628 640743 or maria.sumner@phaseforward.com or Juli Greenwood at 781-672-3137 or jgreenwood@chenpr.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!